ArticleJBMR plus2026
Evaluating the osteoclastogenic potential of peripheral blood mononuclear cells in children with chronic nonbacterial osteomyelitis.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".Current opinion in rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease in which osteoclastogenesis may play a critical role. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has been shown to inhibit osteoclastogenesis derived from PBMCs. Our objectives were to determine whether osteoclastogenesis is altered (1) in patient PBMCs, (2) by patient serum, and (3) by a CTLA-4 analog, abatacept. Patients with active or inactive CNO, inactive juvenile idiopathic arthritis (JIA), and healthy controls were enrolled. CD14+ monocytes isolated from healthy donors were incubated with serum samples, macrophage colony-stimulating factor (MCSF), and RANKL for 7 d. Tartrate-resistant acid phosphatase positive cells with 3 or more nuclei were counted and compared across samples. In another study, PBMCs from patients were incubated with MCSF and RANKL with or without abatacept for 7 d. A log-linear mixed model considering patients nested within block random effects was applied to compare the osteoclast counts, RANKL, and OPG levels across groups. Dunn's multiple comparisons test was performed using the Benjamini-Hochberg method. No significant difference was seen across 4 groups within the serum study. The highest serum concentration was associated with more osteoclasts compared to the lowest concentration (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.